Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vir Biotechnology Inc VIR

Healthcare Biotechnology
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical... see more

Recent & Breaking News (NDAQ:VIR)

Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

GlobeNewswire May 8, 2020

Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference

GlobeNewswire May 7, 2020

Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19

Business Wire May 4, 2020

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020

GlobeNewswire April 28, 2020

VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

GlobeNewswire April 15, 2020

Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218

GlobeNewswire April 8, 2020

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

GlobeNewswire April 6, 2020

Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19

Business Wire March 30, 2020

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire March 26, 2020

Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19

GlobeNewswire March 25, 2020

Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19

GlobeNewswire March 12, 2020

Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses

GlobeNewswire March 11, 2020

Vir Biotechnology to Present at Barclays Global Healthcare Conference

GlobeNewswire March 10, 2020

Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19

GlobeNewswire February 25, 2020

Vir Biotechnology to Present at 40th Annual Cowen Healthcare Conference

GlobeNewswire February 24, 2020

Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2

GlobeNewswire February 12, 2020

Vir Biotechnology applying multiple platforms to address public heath risk from Wuhan coronavirus

GlobeNewswire January 22, 2020

Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 13, 2020

Vir Biotechnology to Present at 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2020

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results

GlobeNewswire November 19, 2019